[{"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-001", "question": "A 45-year-old man with a history of bipolar disorder presents with acute agitation, auditory hallucinations, and disorganized thinking after discontinuing his lithium therapy 2 weeks ago. He has a serum creatinine of 1.8 mg/dL and reports recent use of ibuprofen for headaches. Which of the following is the most appropriate initial management?", "options": ["Administer haloperidol intramuscularly", "Restart lithium at half the previous dose", "Initiate valproic acid orally", "Perform hemodialysis", "Administer lorazepam intravenously"], "answer": "D", "answer_index": 3, "explanation": "Hemodialysis is indicated due to lithium toxicity exacerbated by NSAID-induced renal impairment, leading to elevated lithium levels causing neurotoxicity. Haloperidol and lorazepam address symptoms but not the underlying toxicity, while restarting lithium or starting valproic acid risks worsening the condition without clearance.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Miskeyed / no defensible answer from given stem\\nKey stem clues: Recent discontinuation of lithium 2 weeks ago; current symptoms of agitation, hallucinations, disorganized thinking (mania/psychosis); creatinine 1.8 mg/dL; recent NSAID (ibuprofen) use. There is no serum lithium level, no mention of ongoing lithium use, and the drug was stopped 2 weeks prior.\\nMain logical issues: The explanation assumes lithium toxicity requiring hemodialysis, but the stem explicitly says lithium was discontinued 2 weeks ago, which strongly argues against acute lithium toxicity from current dosing. Without a lithium level or continued dosing, dialysis is not justified. Other options (IM haloperidol or IV lorazepam) could be initial symptomatic management of acute agitation/mania; the stem gives no data to clearly privilege dialysis over standard behavioral control. Thus no option clearly and uniquely fits what is actually described.\\nMain medical accuracy issues: Hemodialysis is not indicated for a patient off lithium for 2 weeks with no evidence of current lithium elevation. The rationale is pathophysiologically incorrect for the stem as written.\\nMinimal fix: Add data showing current lithium therapy with a markedly elevated lithium level and signs of toxicity, or change the key to an acute agitation management option and revise the explanation accordingly.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Miskeyed / no defensible answer from given stem\nKey stem clues: Recent discontinuation of lithium 2 weeks ago; current symptoms of agitation, hallucinations, disorganized thinking (mania/psychosis); creatinine 1.8 mg/dL; recent NSAID (ibuprofen) use. There is no serum lithium level, no mention of ongoing lithium use, and the drug was stopped 2 weeks prior.\nMain logical issues: The explanation assumes lithium toxicity requiring hemodialysis, but the stem explicitly says lithium was discontinued 2 weeks ago, which strongly argues against acute lithium toxicity from current dosing. Without a lithium level or continued dosing, dialysis is not justified. Other options (IM haloperidol or IV lorazepam) could be initial symptomatic management of acute agitation/mania; the stem gives no data to clearly privilege dialysis over standard behavioral control. Thus no option clearly and uniquely fits what is actually described.\nMain medical accuracy issues: Hemodialysis is not indicated for a patient off lithium for 2 weeks with no evidence of current lithium elevation. The rationale is pathophysiologically incorrect for the stem as written.\nMinimal fix: Add data showing current lithium therapy with a markedly elevated lithium level and signs of toxicity, or change the key to an acute agitation management option and revise the explanation accordingly.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-002", "question": "A 32-year-old woman with schizophrenia on clozapine develops fever, tachycardia, and muscle rigidity. Laboratory findings include elevated creatine kinase and leukocytosis. Which rare adverse effect is most likely responsible, and what is the next step in management?", "options": ["Agranulocytosis; discontinue clozapine and start G-CSF", "Neuroleptic malignant syndrome; administer dantrolene and bromocriptine", "Serotonin syndrome; give cyproheptadine", "Catatonia; initiate electroconvulsive therapy", "Myocarditis; perform echocardiography and stop clozapine"], "answer": "B", "answer_index": 1, "explanation": "Neuroleptic malignant syndrome is the diagnosis, requiring immediate supportive care with dantrolene for rigidity and bromocriptine for dopamine agonism. Agranulocytosis presents with infection without rigidity, serotonin syndrome lacks CK elevation typically, catatonia is behavioral, and myocarditis involves cardiac symptoms primarily.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient on clozapine (a dopamine antagonist), with fever, tachycardia, marked muscle rigidity, elevated creatine kinase, and leukocytosis. This classic tetrad (hyperthermia, “lead-pipe” rigidity, autonomic instability, lab evidence of muscle breakdown and systemic stress) is characteristic of neuroleptic malignant syndrome (NMS), a rare but life-threatening antipsychotic adverse effect. The keyed answer (B) correctly identifies NMS and appropriate pharmacologic management with dantrolene (reduces muscle rigidity/heat production) and bromocriptine (dopamine agonist). Other options: A (agranulocytosis) would present with infection, neutropenia, not rigidity/CK; C (serotonin syndrome) more typically has hyperreflexia, clonus, GI symptoms and different drug trigger; D (catatonia) is a behavioral/motor syndrome without hyperCKemia; E (myocarditis) would feature chest pain, dyspnea, arrhythmia. No options better fit the findings.\\nMain logical issues: Minor—serotonin syndrome can have elevated CK but overall phenotype and clozapine trigger favor NMS.\\nMain medical accuracy issues: None significant; management is acceptable and board-consistent.\\nMinimal fix: Add “and immediately discontinue clozapine” to option B to emphasize drug cessation as first-line management of NMS.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient on clozapine (a dopamine antagonist), with fever, tachycardia, marked muscle rigidity, elevated creatine kinase, and leukocytosis. This classic tetrad (hyperthermia, “lead-pipe” rigidity, autonomic instability, lab evidence of muscle breakdown and systemic stress) is characteristic of neuroleptic malignant syndrome (NMS), a rare but life-threatening antipsychotic adverse effect. The keyed answer (B) correctly identifies NMS and appropriate pharmacologic management with dantrolene (reduces muscle rigidity/heat production) and bromocriptine (dopamine agonist). Other options: A (agranulocytosis) would present with infection, neutropenia, not rigidity/CK; C (serotonin syndrome) more typically has hyperreflexia, clonus, GI symptoms and different drug trigger; D (catatonia) is a behavioral/motor syndrome without hyperCKemia; E (myocarditis) would feature chest pain, dyspnea, arrhythmia. No options better fit the findings.\nMain logical issues: Minor—serotonin syndrome can have elevated CK but overall phenotype and clozapine trigger favor NMS.\nMain medical accuracy issues: None significant; management is acceptable and board-consistent.\nMinimal fix: Add “and immediately discontinue clozapine” to option B to emphasize drug cessation as first-line management of NMS.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-003", "question": "A 65-year-old man undergoes laparoscopic cholecystectomy for acute cholecystitis. Intraoperatively, there is significant bleeding from the cystic artery that is difficult to control. Postoperative imaging reveals a pseudoaneurysm. What is the most appropriate intervention?", "options": ["Endoscopic retrograde cholangiopancreatography with stenting", "Angiographic embolization", "Surgical re-exploration with ligation", "Percutaneous transhepatic cholangiography", "Observation with serial imaging"], "answer": "B", "answer_index": 1, "explanation": "Angiographic embolization is preferred for postoperative pseudoaneurysm to minimize invasiveness and control bleeding effectively. Surgical re-exploration carries higher morbidity, ERCP addresses biliary issues not vascular, PTC is for drainage, and observation risks rupture.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 65-year-old man, laparoscopic cholecystectomy for acute cholecystitis; intraoperative significant bleeding from cystic artery that was difficult to control; postoperative imaging reveals a pseudoaneurysm; question asks for most appropriate intervention. A post-cholecystectomy cystic artery (or hepatic artery branch) pseudoaneurysm is a vascular complication with risk of rupture/hemobilia; modern standard management is minimally invasive endovascular therapy.\\n\\nAngiographic embolization (B) is the standard first-line treatment: it both diagnoses and treats the vascular lesion with lower morbidity than open surgery, and is specifically indicated for pseudoaneurysms in this setting. Surgical re-exploration with ligation (C) is a backup if embolization fails or is unavailable, but is not the best initial choice given higher risk. ERCP (A) and PTC (D) address biliary obstruction/leaks, not vascular pseudoaneurysm. Observation (E) is inappropriate because pseudoaneurysms have substantial rupture risk.\\n\\nNo major medical inaccuracies are present; the teaching point is current and appropriate. \\n\\nMinimal fix: Specify “cystic artery pseudoaneurysm” in the stem to more clearly link the lesion to the intraoperative bleeding source, but this is not essential for answer discrimination.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 65-year-old man, laparoscopic cholecystectomy for acute cholecystitis; intraoperative significant bleeding from cystic artery that was difficult to control; postoperative imaging reveals a pseudoaneurysm; question asks for most appropriate intervention. A post-cholecystectomy cystic artery (or hepatic artery branch) pseudoaneurysm is a vascular complication with risk of rupture/hemobilia; modern standard management is minimally invasive endovascular therapy.\n\nAngiographic embolization (B) is the standard first-line treatment: it both diagnoses and treats the vascular lesion with lower morbidity than open surgery, and is specifically indicated for pseudoaneurysms in this setting. Surgical re-exploration with ligation (C) is a backup if embolization fails or is unavailable, but is not the best initial choice given higher risk. ERCP (A) and PTC (D) address biliary obstruction/leaks, not vascular pseudoaneurysm. Observation (E) is inappropriate because pseudoaneurysms have substantial rupture risk.\n\nNo major medical inaccuracies are present; the teaching point is current and appropriate. \n\nMinimal fix: Specify “cystic artery pseudoaneurysm” in the stem to more clearly link the lesion to the intraoperative bleeding source, but this is not essential for answer discrimination.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-004", "question": "A 50-year-old woman with Crohn's disease presents with an enterocutaneous fistula after ileocolic resection. She is hemodynamically stable but has high-output fistula drainage. Which management strategy is most effective for promoting spontaneous closure?", "options": ["Total parenteral nutrition and somatostatin analog", "Immediate surgical closure with bowel resection", "Antibiotic therapy with abscess drainage", "Hyperbaric oxygen therapy", "Fibrin glue injection into the fistula tract"], "answer": "A", "answer_index": 0, "explanation": "TPN and somatostatin analogs reduce gastrointestinal secretions and promote fistula healing in high-output cases. Surgical closure is reserved for failures, antibiotics address infection not closure, hyperbaric oxygen lacks evidence, and fibrin glue is for low-output fistulas.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 50-year-old woman; Crohn’s disease; postoperative enterocutaneous fistula after ileocolic resection; hemodynamically stable; high-output fistula drainage; question asks for strategy “most effective for promoting spontaneous closure.” Standard management of high-output enterocutaneous fistulas prioritizes nonoperative optimization: control sepsis, protect skin, and decrease GI secretions with bowel rest/TPN and pharmacologic agents (somatostatin or octreotide) to enhance likelihood of spontaneous closure before considering elective surgery.\\n\\nChoice A aligns directly with this evidence-based approach. B (immediate surgical closure) is inappropriate early in the course for a high-output postoperative fistula unless unstable or uncontrolled sepsis; early surgery has higher failure and complication rates. C (antibiotics with abscess drainage) addresses sepsis control but not specifically closure promotion and is incomplete given high output. D (hyperbaric oxygen) is not standard or well-evidenced for enterocutaneous fistula closure. E (fibrin glue) is primarily used for low-output, simple fistulas; high output predicts poor success.\\n\\nMain medical accuracy issues: Minor—item does not mention timing/duration of fistula or presence/absence of sepsis, but the key teaching remains correct.\\n\\nMinimal fix: Explicitly state “no evidence of ongoing sepsis or undrained abscess” to clarify that optimization with TPN and somatostatin is the preferred next step over immediate surgery.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 50-year-old woman; Crohn’s disease; postoperative enterocutaneous fistula after ileocolic resection; hemodynamically stable; high-output fistula drainage; question asks for strategy “most effective for promoting spontaneous closure.” Standard management of high-output enterocutaneous fistulas prioritizes nonoperative optimization: control sepsis, protect skin, and decrease GI secretions with bowel rest/TPN and pharmacologic agents (somatostatin or octreotide) to enhance likelihood of spontaneous closure before considering elective surgery.\n\nChoice A aligns directly with this evidence-based approach. B (immediate surgical closure) is inappropriate early in the course for a high-output postoperative fistula unless unstable or uncontrolled sepsis; early surgery has higher failure and complication rates. C (antibiotics with abscess drainage) addresses sepsis control but not specifically closure promotion and is incomplete given high output. D (hyperbaric oxygen) is not standard or well-evidenced for enterocutaneous fistula closure. E (fibrin glue) is primarily used for low-output, simple fistulas; high output predicts poor success.\n\nMain medical accuracy issues: Minor—item does not mention timing/duration of fistula or presence/absence of sepsis, but the key teaching remains correct.\n\nMinimal fix: Explicitly state “no evidence of ongoing sepsis or undrained abscess” to clarify that optimization with TPN and somatostatin is the preferred next step over immediate surgery.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-005", "question": "A 60-year-old man with diabetes presents with sudden painless vision loss in the right eye. Fundoscopy shows macular edema and neovascularization at the disc. Optical coherence tomography confirms vitreomacular traction. What is the most appropriate initial treatment?", "options": ["Intravitreal anti-VEGF injection", "Panretinal photocoagulation", "Pars plana vitrectomy", "Intravitreal corticosteroid", "Observation with follow-up"], "answer": "C", "answer_index": 2, "explanation": "Pars plana vitrectomy addresses vitreomacular traction in proliferative diabetic retinopathy with macular involvement, relieving traction and allowing further therapy. Anti-VEGF and laser treat neovascularization but not traction, corticosteroids risk complications, and observation may worsen vision.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 60-year-old man with diabetes, sudden painless monocular vision loss, macular edema, neovascularization at the disc (proliferative diabetic retinopathy), and OCT-confirmed vitreomacular traction. These together indicate tractional involvement of the macula in PDR causing vision loss.\\nIn this context, the most appropriate initial treatment is pars plana vitrectomy to surgically relieve vitreomacular traction threatening/affecting the macula and vision; this is standard for tractional maculopathy in PDR. Anti-VEGF (A) and panretinal photocoagulation (B) are important in PDR but do not directly relieve established vitreomacular traction and would not be the primary step when acute vision loss is from traction. Intravitreal corticosteroid (D) is not first-line here and poses risks (elevated IOP, cataract). Observation (E) is inappropriate given sudden vision loss and traction.\\nThe question provides sufficient specific findings (macular involvement plus traction on OCT) to uniquely favor surgical intervention. Medical content and reasoning are consistent with typical retina management principles.\\nMinimal fix: Clarify in the stem that the traction is causing decreased foveal contour/retinal distortion corresponding to the vision loss, or state “tractional maculopathy involving the fovea,” to remove any residual ambiguity about indication for vitrectomy.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 60-year-old man with diabetes, sudden painless monocular vision loss, macular edema, neovascularization at the disc (proliferative diabetic retinopathy), and OCT-confirmed vitreomacular traction. These together indicate tractional involvement of the macula in PDR causing vision loss.\nIn this context, the most appropriate initial treatment is pars plana vitrectomy to surgically relieve vitreomacular traction threatening/affecting the macula and vision; this is standard for tractional maculopathy in PDR. Anti-VEGF (A) and panretinal photocoagulation (B) are important in PDR but do not directly relieve established vitreomacular traction and would not be the primary step when acute vision loss is from traction. Intravitreal corticosteroid (D) is not first-line here and poses risks (elevated IOP, cataract). Observation (E) is inappropriate given sudden vision loss and traction.\nThe question provides sufficient specific findings (macular involvement plus traction on OCT) to uniquely favor surgical intervention. Medical content and reasoning are consistent with typical retina management principles.\nMinimal fix: Clarify in the stem that the traction is causing decreased foveal contour/retinal distortion corresponding to the vision loss, or state “tractional maculopathy involving the fovea,” to remove any residual ambiguity about indication for vitrectomy.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-006", "question": "A 25-year-old athlete sustains a tibial plateau fracture with associated meniscal tear and ACL disruption. Intraoperative findings include a depressed lateral plateau fragment. What is the optimal surgical approach to restore joint congruity?", "options": ["External fixation with delayed internal fixation", "Arthroscopic-assisted reduction and internal fixation", "Open reduction with bone grafting and buttress plating", "Total knee arthroplasty", "Nonoperative management with bracing"], "answer": "C", "answer_index": 2, "explanation": "Open reduction with bone grafting and buttress plating restores articular surface in complex tibial plateau fractures with depression. Arthroscopic assistance is for simpler cases, external fixation is temporary, arthroplasty is for older patients, and nonoperative risks malunion.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Orthopedic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 25-year-old athlete; tibial plateau fracture; depressed lateral plateau fragment; associated meniscal tear and ACL disruption; question asks for “optimal surgical approach to restore joint congruity.” These features describe a high-energy, complex articular injury in a young, active patient requiring anatomic reduction and stable fixation.\\n\\nMost likely management: Open reduction, elevation of the depressed articular surface, bone grafting to support the subchondral void, and buttress plating for stable fixation is standard of care for comminuted/depressed plateau fractures in young patients.\\n\\nChoice C matches this and is clearly superior. B (arthroscopic-assisted fixation) is generally reserved for less complex, minimally displaced fractures; here, open access is needed for elevation, grafting, and hardware. A (external fixation) is a temporary or damage-control measure, not definitive for joint congruity. D (total knee arthroplasty) is inappropriate in a 25-year-old athlete. E (nonoperative) is not appropriate for a depressed articular fracture with ligamentous and meniscal injuries.\\n\\nNo major logical or medical inaccuracies. Minimal fix: Specify Schatzker type (e.g., “Schatzker type II depressed lateral plateau fracture”) to further clarify the complexity requiring open reduction and buttress plating.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 25-year-old athlete; tibial plateau fracture; depressed lateral plateau fragment; associated meniscal tear and ACL disruption; question asks for “optimal surgical approach to restore joint congruity.” These features describe a high-energy, complex articular injury in a young, active patient requiring anatomic reduction and stable fixation.\n\nMost likely management: Open reduction, elevation of the depressed articular surface, bone grafting to support the subchondral void, and buttress plating for stable fixation is standard of care for comminuted/depressed plateau fractures in young patients.\n\nChoice C matches this and is clearly superior. B (arthroscopic-assisted fixation) is generally reserved for less complex, minimally displaced fractures; here, open access is needed for elevation, grafting, and hardware. A (external fixation) is a temporary or damage-control measure, not definitive for joint congruity. D (total knee arthroplasty) is inappropriate in a 25-year-old athlete. E (nonoperative) is not appropriate for a depressed articular fracture with ligamentous and meniscal injuries.\n\nNo major logical or medical inaccuracies. Minimal fix: Specify Schatzker type (e.g., “Schatzker type II depressed lateral plateau fracture”) to further clarify the complexity requiring open reduction and buttress plating.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-007", "question": "A 55-year-old woman with multiple sclerosis presents with progressive spastic paraparesis and urinary incontinence. MRI shows a syrinx from C4 to T2 without Chiari malformation. What is the most likely underlying mechanism, and appropriate management?", "options": ["Post-traumatic syrinx; syringoperitoneal shunting", "Idiopathic syringomyelia; conservative monitoring", "Tumoral syrinx; biopsy and resection", "Inflammatory syrinx due to MS; high-dose steroids", "Arachnoiditis-related; laminectomy with adhesiolysis"], "answer": "A", "answer_index": 0, "explanation": "Post-traumatic syrinx in MS context likely from prior demyelination scars disrupting CSF flow, managed with shunting to prevent progression. Idiopathic lacks MS history, tumoral requires mass evidence, steroids treat acute flares not syrinx, adhesiolysis is for specific scarring.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No defensible answer)\\nVerdict on keyed answer: Misleading/incorrect; no option is clearly defensible as best based on the stem.\\n\\nKey stem clues: 55-year-old woman, known multiple sclerosis, progressive spastic paraparesis and urinary incontinence, MRI: syrinx C4–T2, explicitly “without Chiari malformation.” No history of trauma, tumor, prior surgery, or arachnoiditis is given.\\n\\nMain logical issues: The item asks for “most likely underlying mechanism and appropriate management,” yet the stem provides no evidence of trauma (A), tumor (C), or arachnoiditis (E). The explanation for A invents a mechanism (“post-traumatic syrinx…from prior demyelination scars”) that is not standard; MS plaques do not equate to post-traumatic syringomyelia. Idiopathic syringomyelia (B) with initial conservative monitoring is a plausible, arguably most reasonable choice given absence of Chiari or other causes, but the key is A. Thus there is no clearly defensible keyed answer, and the keyed option relies on nonstandard, unsupported pathophysiology.\\n\\nMain medical accuracy issues: Mischaracterizes MS as a cause of “post-traumatic” syrinx and overstates shunting as default management.\\n\\nMinimal fix: Add clear history of significant remote cervical trauma and specify progressive deficits despite prior observation to justify A, or change the key to B and adjust the explanation to idiopathic syringomyelia with observation.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No defensible answer)\nVerdict on keyed answer: Misleading/incorrect; no option is clearly defensible as best based on the stem.\n\nKey stem clues: 55-year-old woman, known multiple sclerosis, progressive spastic paraparesis and urinary incontinence, MRI: syrinx C4–T2, explicitly “without Chiari malformation.” No history of trauma, tumor, prior surgery, or arachnoiditis is given.\n\nMain logical issues: The item asks for “most likely underlying mechanism and appropriate management,” yet the stem provides no evidence of trauma (A), tumor (C), or arachnoiditis (E). The explanation for A invents a mechanism (“post-traumatic syrinx…from prior demyelination scars”) that is not standard; MS plaques do not equate to post-traumatic syringomyelia. Idiopathic syringomyelia (B) with initial conservative monitoring is a plausible, arguably most reasonable choice given absence of Chiari or other causes, but the key is A. Thus there is no clearly defensible keyed answer, and the keyed option relies on nonstandard, unsupported pathophysiology.\n\nMain medical accuracy issues: Mischaracterizes MS as a cause of “post-traumatic” syrinx and overstates shunting as default management.\n\nMinimal fix: Add clear history of significant remote cervical trauma and specify progressive deficits despite prior observation to justify A, or change the key to B and adjust the explanation to idiopathic syringomyelia with observation.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-008", "question": "A 40-year-old man with epilepsy on carbamazepine develops diplopia, ataxia, and nystagmus. Serum levels are therapeutic, but free fraction is elevated. What is the most likely cause, and adjustment needed?", "options": ["Hyponatremia; restrict fluids", "Drug interaction with protein binding; reduce dose", "Autoinduction; increase dose", "Hepatic failure; switch to alternative", "Renal impairment; hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "Elevated free carbamazepine due to hypoalbuminemia or displacement increases toxicity despite therapeutic total levels, requiring dose reduction. Hyponatremia causes different symptoms, autoinduction lowers levels, hepatic failure elevates total levels, renal issues don't directly affect binding.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 40-year-old man on carbamazepine; neurologic toxicity signs (diplopia, ataxia, nystagmus); total serum levels in the therapeutic range; free fraction elevated. This directly points to a situation where protein binding is altered (e.g., hypoalbuminemia or displacement by another drug), so free (active) drug is high despite normal total level. The appropriate management is to reduce the carbamazepine dose rather than increase it or switch automatically.\\nOption B matches this mechanism and management. Option A (hyponatremia) would produce CNS symptoms but is not connected to “elevated free fraction”; also, the question asks cause and adjustment specifically in terms of drug levels. Option C (autoinduction) would lower, not raise, free levels. Option D (hepatic failure) would more typically raise total levels with metabolism impairment, not selectively the free fraction. Option E (renal impairment/hemodialysis) is less relevant because carbamazepine is hepatically metabolized and highly protein-bound; dialysis is not first-line.\\nMain medical issue: minor oversimplification (doesn’t mention measuring albumin or interacting drugs) but conceptually correct.\\nMinimal fix: Explicitly mention a new co-medication that displaces carbamazepine from albumin to strengthen the causal link to option B.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 40-year-old man on carbamazepine; neurologic toxicity signs (diplopia, ataxia, nystagmus); total serum levels in the therapeutic range; free fraction elevated. This directly points to a situation where protein binding is altered (e.g., hypoalbuminemia or displacement by another drug), so free (active) drug is high despite normal total level. The appropriate management is to reduce the carbamazepine dose rather than increase it or switch automatically.\nOption B matches this mechanism and management. Option A (hyponatremia) would produce CNS symptoms but is not connected to “elevated free fraction”; also, the question asks cause and adjustment specifically in terms of drug levels. Option C (autoinduction) would lower, not raise, free levels. Option D (hepatic failure) would more typically raise total levels with metabolism impairment, not selectively the free fraction. Option E (renal impairment/hemodialysis) is less relevant because carbamazepine is hepatically metabolized and highly protein-bound; dialysis is not first-line.\nMain medical issue: minor oversimplification (doesn’t mention measuring albumin or interacting drugs) but conceptually correct.\nMinimal fix: Explicitly mention a new co-medication that displaces carbamazepine from albumin to strengthen the causal link to option B.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-009", "question": "A 35-year-old woman presents with erythematous plaques on the trunk and positive Darier's sign. Biopsy shows mast cell infiltration. Systemic symptoms include flushing and diarrhea. What is the most appropriate long-term management?", "options": ["Oral cromolyn sodium", "Imatinib therapy", "Omalizumab injections", "Bone marrow transplantation", "Interferon-alpha"], "answer": "A", "answer_index": 0, "explanation": "Oral cromolyn stabilizes mast cells in cutaneous mastocytosis with systemic features, reducing mediator release. Imatinib is for KIT mutations not present here, omalizumab for allergic components, transplantation for aggressive forms, interferon for indolent systemic mastocytosis.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified, tending toward M)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: 35-year-old woman, erythematous plaques with positive Darier sign, biopsy with mast cell infiltration, plus systemic mediator-related symptoms (flushing, diarrhea). The question asks for the most appropriate long-term management. This constellation suggests at least indolent systemic mastocytosis or cutaneous mastocytosis with systemic mediator symptoms.\\n\\nThe key (oral cromolyn) is indeed a standard, commonly used long-term mast-cell stabilizer that improves GI symptoms and is reasonable first-line symptomatic therapy. However, the stem does not characterize disease extent (purely cutaneous vs indolent vs aggressive systemic), KIT mutation status, or severity/refractoriness. In many current practices, H1/H2 blockers and leukotriene antagonists are first-line; cromolyn is one of several options and not uniquely the “most appropriate” based on the limited information. Omalizumab is also used for mediator symptoms in some patients; without more detail, A and C can both be defensible.\\n\\nMedical accuracy is generally sound; no clearly false associations, but the explanation overstates specificity of choices for given subtypes.\\n\\nMinimal fix: Explicitly state this is indolent/systemic mastocytosis with predominant GI mediator symptoms refractory to H1/H2 blockers, and ask for the best mast-cell–stabilizing oral therapy, or adjust options to remove similarly reasonable symptomatic agents.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified, tending toward M)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: 35-year-old woman, erythematous plaques with positive Darier sign, biopsy with mast cell infiltration, plus systemic mediator-related symptoms (flushing, diarrhea). The question asks for the most appropriate long-term management. This constellation suggests at least indolent systemic mastocytosis or cutaneous mastocytosis with systemic mediator symptoms.\n\nThe key (oral cromolyn) is indeed a standard, commonly used long-term mast-cell stabilizer that improves GI symptoms and is reasonable first-line symptomatic therapy. However, the stem does not characterize disease extent (purely cutaneous vs indolent vs aggressive systemic), KIT mutation status, or severity/refractoriness. In many current practices, H1/H2 blockers and leukotriene antagonists are first-line; cromolyn is one of several options and not uniquely the “most appropriate” based on the limited information. Omalizumab is also used for mediator symptoms in some patients; without more detail, A and C can both be defensible.\n\nMedical accuracy is generally sound; no clearly false associations, but the explanation overstates specificity of choices for given subtypes.\n\nMinimal fix: Explicitly state this is indolent/systemic mastocytosis with predominant GI mediator symptoms refractory to H1/H2 blockers, and ask for the best mast-cell–stabilizing oral therapy, or adjust options to remove similarly reasonable symptomatic agents.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-010", "question": "A 55-year-old man with prostate cancer on androgen deprivation therapy develops urinary retention. Cystoscopy reveals bladder neck contracture. What is the most effective definitive treatment?", "options": ["Transurethral incision of the bladder neck", "Suprapubic catheter placement", "Alpha-blocker therapy", "Intravesical botulinum toxin injection", "Urethral dilation with sounds"], "answer": "A", "answer_index": 0, "explanation": "Transurethral incision relieves bladder neck contracture post-ADT, providing durable relief. Suprapubic catheter is palliative, alpha-blockers ineffective for scarring, botulinum for detrusor issues, dilation temporary and recurrent.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 55-year-old man with prostate cancer on androgen deprivation therapy, develops urinary retention; cystoscopy shows a bladder neck contracture; question asks for the most effective definitive treatment. Bladder neck contracture is a fixed anatomic obstruction (scar) at the bladder outlet.\\n\\nMost likely mechanism: Fibrotic narrowing of the bladder neck causing outlet obstruction, best managed by endoscopic incision/resection of the scarred region.\\n\\nChoice A (transurethral incision of the bladder neck) directly addresses the fibrotic obstruction and is standard definitive management for bladder neck contracture, offering the best chance at durable relief.\\n\\nOther options: B (suprapubic catheter) is decompressive/palliative, not definitive. C (alpha-blocker) targets dynamic smooth muscle tone, not fixed scar. D (intravesical botulinum toxin) is used for detrusor overactivity, not outlet fibrosis. E (urethral dilation) has high recurrence and is less definitive than surgical incision.\\n\\nMain medical accuracy issue: Minor—bladder neck contracture is more classically post-prostate surgery/radiation than specifically “post-ADT,” but this does not affect the core management principle.\\n\\nMinimal fix: Clarify etiology, e.g., “after radical prostatectomy” instead of “on androgen deprivation therapy,” to better align with typical causes of bladder neck contracture.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 55-year-old man with prostate cancer on androgen deprivation therapy, develops urinary retention; cystoscopy shows a bladder neck contracture; question asks for the most effective definitive treatment. Bladder neck contracture is a fixed anatomic obstruction (scar) at the bladder outlet.\n\nMost likely mechanism: Fibrotic narrowing of the bladder neck causing outlet obstruction, best managed by endoscopic incision/resection of the scarred region.\n\nChoice A (transurethral incision of the bladder neck) directly addresses the fibrotic obstruction and is standard definitive management for bladder neck contracture, offering the best chance at durable relief.\n\nOther options: B (suprapubic catheter) is decompressive/palliative, not definitive. C (alpha-blocker) targets dynamic smooth muscle tone, not fixed scar. D (intravesical botulinum toxin) is used for detrusor overactivity, not outlet fibrosis. E (urethral dilation) has high recurrence and is less definitive than surgical incision.\n\nMain medical accuracy issue: Minor—bladder neck contracture is more classically post-prostate surgery/radiation than specifically “post-ADT,” but this does not affect the core management principle.\n\nMinimal fix: Clarify etiology, e.g., “after radical prostatectomy” instead of “on androgen deprivation therapy,” to better align with typical causes of bladder neck contracture.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-011", "question": "A 28-year-old pregnant woman at 32 weeks gestation with major depressive disorder relapses after stopping sertraline. She has suicidal ideation. What is the most appropriate pharmacologic intervention?", "options": ["Restart sertraline at previous dose", "Initiate electroconvulsive therapy", "Start bupropion extended-release", "Prescribe mirtazapine", "Use transcranial magnetic stimulation"], "answer": "B", "answer_index": 1, "explanation": "ECT is safe and effective for severe depression in pregnancy with suicidality, avoiding fetal medication exposure. Sertraline risks neonatal adaptation syndrome, bupropion seizure risk, mirtazapine sedation, TMS less evidence in acute suicidality.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: 28-year-old at 32 weeks’ gestation, known major depressive disorder, previously well-controlled on sertraline, relapsed after stopping, now has suicidal ideation. Question asks for “most appropriate pharmacologic intervention.” Options mix medications with nonpharmacologic brain stimulation (ECT, TMS).\\n\\nMedically, severe depression with suicidal ideation in pregnancy is indeed a strong indication for ECT and ECT is safe and effective. However, the stem specifically asks for a pharmacologic intervention. ECT is not pharmacotherapy; among the listed options, restarting the previously effective SSRI (sertraline) at 32 weeks is guideline-consistent and commonly preferred, with neonatal adaptation generally manageable. Thus A is the best pharmacologic choice, while B is best nonpharmacologic. Because the question type is “single best answer,” this wording creates two reasonable “best” answers depending on whether one prioritizes stem wording or safety in severe suicidality.\\n\\nMain logical issue: mismatch between stem request (pharmacologic) and keyed nonpharmacologic answer; leads to ambiguity. Medical content is otherwise accurate, though risks of sertraline are overstated in the explanation.\\n\\nMinimal fix: Change the stem to “What is the most appropriate next treatment?” or change the key to A and adjust rationale accordingly.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: 28-year-old at 32 weeks’ gestation, known major depressive disorder, previously well-controlled on sertraline, relapsed after stopping, now has suicidal ideation. Question asks for “most appropriate pharmacologic intervention.” Options mix medications with nonpharmacologic brain stimulation (ECT, TMS).\n\nMedically, severe depression with suicidal ideation in pregnancy is indeed a strong indication for ECT and ECT is safe and effective. However, the stem specifically asks for a pharmacologic intervention. ECT is not pharmacotherapy; among the listed options, restarting the previously effective SSRI (sertraline) at 32 weeks is guideline-consistent and commonly preferred, with neonatal adaptation generally manageable. Thus A is the best pharmacologic choice, while B is best nonpharmacologic. Because the question type is “single best answer,” this wording creates two reasonable “best” answers depending on whether one prioritizes stem wording or safety in severe suicidality.\n\nMain logical issue: mismatch between stem request (pharmacologic) and keyed nonpharmacologic answer; leads to ambiguity. Medical content is otherwise accurate, though risks of sertraline are overstated in the explanation.\n\nMinimal fix: Change the stem to “What is the most appropriate next treatment?” or change the key to A and adjust rationale accordingly.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-012", "question": "A 60-year-old man with alcohol use disorder presents with confabulation, ophthalmoplegia, and ataxia. MRI shows mamillary body atrophy. What is the underlying deficiency, and specific treatment?", "options": ["Vitamin B12; intramuscular cyanocobalamin", "Thiamine; intravenous thiamine", "Folate; oral folic acid", "Vitamin E; alpha-tocopherol", "Magnesium; intravenous magnesium sulfate"], "answer": "B", "answer_index": 1, "explanation": "Thiamine deficiency causes Wernicke-Korsakoff syndrome, treated urgently with IV thiamine to prevent irreversible damage. B12 deficiency causes subacute combined degeneration, folate anemia, vitamin E ataxia without confabulation, magnesium tremors not ophthalmoplegia.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues are alcohol use disorder, triad of confabulation, ophthalmoplegia, and ataxia, plus MRI showing mammillary body atrophy—classic for Wernicke–Korsakoff syndrome. The underlying deficiency is thiamine (vitamin B1), and standard acute treatment is parenteral (usually IV) thiamine before glucose to prevent progression/irreversibility. Option B states both the correct deficient vitamin and appropriate urgent route, and it is clearly superior to all alternatives.\\nOther options: A (B12/IM) corresponds to subacute combined degeneration, not this triad; C (folate) causes megaloblastic anemia, not ophthalmoplegia/confabulation; D (vitamin E) can cause ataxia but not this full syndrome or mammillary body atrophy; E (magnesium) is not the primary deficiency and does not explain the imaging or clinical triad.\\nNo internal contradictions or need for unstated assumptions; diagnosis and management are straightforward and consistent with board standards.\\nMinimal fix: Add “administered prior to glucose-containing fluids” to the explanation (or stem) to reinforce the key management nuance without changing the correct option.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues are alcohol use disorder, triad of confabulation, ophthalmoplegia, and ataxia, plus MRI showing mammillary body atrophy—classic for Wernicke–Korsakoff syndrome. The underlying deficiency is thiamine (vitamin B1), and standard acute treatment is parenteral (usually IV) thiamine before glucose to prevent progression/irreversibility. Option B states both the correct deficient vitamin and appropriate urgent route, and it is clearly superior to all alternatives.\nOther options: A (B12/IM) corresponds to subacute combined degeneration, not this triad; C (folate) causes megaloblastic anemia, not ophthalmoplegia/confabulation; D (vitamin E) can cause ataxia but not this full syndrome or mammillary body atrophy; E (magnesium) is not the primary deficiency and does not explain the imaging or clinical triad.\nNo internal contradictions or need for unstated assumptions; diagnosis and management are straightforward and consistent with board standards.\nMinimal fix: Add “administered prior to glucose-containing fluids” to the explanation (or stem) to reinforce the key management nuance without changing the correct option.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-013", "question": "A 42-year-old woman undergoes Whipple procedure for pancreatic adenocarcinoma. Postoperatively, she develops delayed gastric emptying with high nasogastric output. What is the most effective prokinetic agent?", "options": ["Metoclopramide intravenously", "Erythromycin orally", "Domperidone orally", "Prucalopride", "Octreotide subcutaneously"], "answer": "B", "answer_index": 1, "explanation": "Erythromycin acts as a motilin agonist to enhance gastric motility in post-Whipple delayed emptying. Metoclopramide risks tardive dyskinesia, domperidone cardiac issues, prucalopride for colon, octreotide inhibits motility.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: 42-year-old woman, post-Whipple pancreaticoduodenectomy, delayed gastric emptying with high NG output; asks for “most effective prokinetic agent.” Erythromycin (motilin agonist) and IV metoclopramide are both used to enhance gastric emptying in postoperative/functional gastroparesis. Erythromycin is well known in post-Whipple settings, but metoclopramide is also guideline-supported and FDA-approved for gastroparesis. The item provides no constraints (e.g., duration of therapy, prior failure, QT risk, cost, route requirements) that clearly favor erythromycin over metoclopramide for “most effective.” Citing adverse-effect profiles (tardive dyskinesia, cardiac risk) in the explanation does not resolve “effectiveness” and is not presented in the stem. Thus both A and B are reasonably defensible as best, creating ambiguity. Other options: domperidone has limited US availability and cardiac risk; prucalopride is colonic prokinetic; octreotide inhibits GI motility.\\nMain medical accuracy issues: Explanation overemphasizes risks to eliminate metoclopramide despite no stem cues; the key concept (motilin agonist benefit post-Whipple) is reasonable but not uniquely supported.\\nMinimal fix: Rephrase question to “Which agent is specifically used as a motilin agonist to enhance gastric emptying after Whipple?” or add a prior metoclopramide failure/contraindication in the stem.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: 42-year-old woman, post-Whipple pancreaticoduodenectomy, delayed gastric emptying with high NG output; asks for “most effective prokinetic agent.” Erythromycin (motilin agonist) and IV metoclopramide are both used to enhance gastric emptying in postoperative/functional gastroparesis. Erythromycin is well known in post-Whipple settings, but metoclopramide is also guideline-supported and FDA-approved for gastroparesis. The item provides no constraints (e.g., duration of therapy, prior failure, QT risk, cost, route requirements) that clearly favor erythromycin over metoclopramide for “most effective.” Citing adverse-effect profiles (tardive dyskinesia, cardiac risk) in the explanation does not resolve “effectiveness” and is not presented in the stem. Thus both A and B are reasonably defensible as best, creating ambiguity. Other options: domperidone has limited US availability and cardiac risk; prucalopride is colonic prokinetic; octreotide inhibits GI motility.\nMain medical accuracy issues: Explanation overemphasizes risks to eliminate metoclopramide despite no stem cues; the key concept (motilin agonist benefit post-Whipple) is reasonable but not uniquely supported.\nMinimal fix: Rephrase question to “Which agent is specifically used as a motilin agonist to enhance gastric emptying after Whipple?” or add a prior metoclopramide failure/contraindication in the stem.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-014", "question": "A 70-year-old man with diverticulitis undergoes Hartmann's procedure. Six months later, he presents for reversal but has severe cardiac comorbidity. What is the safest reversal technique?", "options": ["Laparoscopic colostomy reversal with anastomosis", "Open reversal with protective ileostomy", "Endoscopic stenting of the rectal stump", "Percutaneous endoscopic colostomy", "Continued observation"], "answer": "A", "answer_index": 0, "explanation": "Laparoscopic approach minimizes morbidity in high-risk patients for Hartmann's reversal. Open with ileostomy adds procedures, stenting not for reversal, PEC for constipation, observation avoids surgery but maintains stoma.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers, with miskey element)\\nVerdict on keyed answer: Not uniquely determinable; A is debatable and not clearly superior to E.\\nKey stem clues: 70-year-old, prior Hartmann’s for diverticulitis, presenting for reversal, now noted to have severe cardiac comorbidity. Question asks for the “safest reversal technique.” Among options, only A and B are actual reversal operations. C and D are not accepted methods for Hartmann’s reversal. E implies no reversal (continued stoma).\\nMain logical issues: In a severely cardiac‑compromised 70‑year‑old, the genuinely safest management may be to avoid elective major intra‑abdominal surgery altogether; thus E is very defensible as “safest,” while A implies a significant laparoscopic operation with pneumoperitoneum and an anastomosis. The stem does not state that reversal must be done, so the safety framing makes E highly competitive with A, generating at least two plausible best answers. Also, calling laparoscopic reversal clearly safer than no surgery overstates evidence.\\nMain medical accuracy issues: Laparoscopic reversal can reduce morbidity vs open, but “safest” in a high‑risk patient is usually nonoperative management.\\nMinimal fix: Specify the question as “Which operative approach is safest if reversal is pursued?” or change the key to E with rationale about avoiding surgery.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers, with miskey element)\nVerdict on keyed answer: Not uniquely determinable; A is debatable and not clearly superior to E.\nKey stem clues: 70-year-old, prior Hartmann’s for diverticulitis, presenting for reversal, now noted to have severe cardiac comorbidity. Question asks for the “safest reversal technique.” Among options, only A and B are actual reversal operations. C and D are not accepted methods for Hartmann’s reversal. E implies no reversal (continued stoma).\nMain logical issues: In a severely cardiac‑compromised 70‑year‑old, the genuinely safest management may be to avoid elective major intra‑abdominal surgery altogether; thus E is very defensible as “safest,” while A implies a significant laparoscopic operation with pneumoperitoneum and an anastomosis. The stem does not state that reversal must be done, so the safety framing makes E highly competitive with A, generating at least two plausible best answers. Also, calling laparoscopic reversal clearly safer than no surgery overstates evidence.\nMain medical accuracy issues: Laparoscopic reversal can reduce morbidity vs open, but “safest” in a high‑risk patient is usually nonoperative management.\nMinimal fix: Specify the question as “Which operative approach is safest if reversal is pursued?” or change the key to E with rationale about avoiding surgery.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-015", "question": "A 45-year-old woman with rheumatoid arthritis on methotrexate develops corneal melt and peripheral ulcerative keratitis. What is the most appropriate immunosuppressive therapy adjustment?", "options": ["Add infliximab infusion", "Switch to rituximab", "Initiate cyclophosphamide", "Topical cyclosporine", "Systemic corticosteroids with azathioprine"], "answer": "C", "answer_index": 2, "explanation": "Cyclophosphamide is used for severe ocular manifestations in rheumatoid vasculitis like corneal melt. Infliximab for joints, rituximab B-cell depletion insufficient alone, topical for surface, steroids with azathioprine less potent for melt.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 45-year-old woman with established rheumatoid arthritis on methotrexate, now with corneal melt and peripheral ulcerative keratitis—both classic severe, vision-threatening ocular manifestations of rheumatoid vasculitis. The question asks for the most appropriate adjustment in systemic immunosuppression for this life/vision-threatening extra-articular complication.\\n\\nCyclophosphamide (C) is a standard, high-potency cytotoxic immunosuppressant used for severe systemic vasculitis manifestations, including necrotizing scleritis/PUK/corneal melt in RA, usually combined with high-dose systemic glucocorticoids. Among options, it is the clearest escalation for severe vasculitis.\\n\\nOption A (infliximab) is not first-line or uniquely indicated for corneal melt; evidence is limited and it’s more typical for joint disease or other inflammatory conditions. B (rituximab) is used for RA and some vasculitides but is not as classic an exam answer as cyclophosphamide for fulminant vasculitis. D (topical cyclosporine) is inadequate for systemic vasculitis. E (steroids with azathioprine) is less potent than cyclophosphamide for rapidly progressive vasculitis threatening vision.\\n\\nMain medical/logical issues: minor nuance that high-dose systemic steroids plus cyclophosphamide would be most accurate, but within given options, C is clearly best.\\n\\nMinimal fix: Modify option C to “High-dose systemic corticosteroids plus cyclophosphamide” to reflect standard management more precisely.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 45-year-old woman with established rheumatoid arthritis on methotrexate, now with corneal melt and peripheral ulcerative keratitis—both classic severe, vision-threatening ocular manifestations of rheumatoid vasculitis. The question asks for the most appropriate adjustment in systemic immunosuppression for this life/vision-threatening extra-articular complication.\n\nCyclophosphamide (C) is a standard, high-potency cytotoxic immunosuppressant used for severe systemic vasculitis manifestations, including necrotizing scleritis/PUK/corneal melt in RA, usually combined with high-dose systemic glucocorticoids. Among options, it is the clearest escalation for severe vasculitis.\n\nOption A (infliximab) is not first-line or uniquely indicated for corneal melt; evidence is limited and it’s more typical for joint disease or other inflammatory conditions. B (rituximab) is used for RA and some vasculitides but is not as classic an exam answer as cyclophosphamide for fulminant vasculitis. D (topical cyclosporine) is inadequate for systemic vasculitis. E (steroids with azathioprine) is less potent than cyclophosphamide for rapidly progressive vasculitis threatening vision.\n\nMain medical/logical issues: minor nuance that high-dose systemic steroids plus cyclophosphamide would be most accurate, but within given options, C is clearly best.\n\nMinimal fix: Modify option C to “High-dose systemic corticosteroids plus cyclophosphamide” to reflect standard management more precisely.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-016", "question": "A 35-year-old man sustains a humeral shaft fracture with radial nerve palsy. Exploration shows nerve entrapment in the fracture site. What is the optimal management of the nerve injury?", "options": ["Immediate nerve grafting", "Neurolysis and fracture fixation", "Nerve transfer from triceps branch", "Tendon transfer for wrist extension", "Observation with serial EMG"], "answer": "B", "answer_index": 1, "explanation": "Neurolysis frees the entrapped radial nerve during fracture fixation, allowing potential recovery. Grafting for transection, transfer for irreparable, tendon for chronic, observation misses surgical window.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Orthopedic Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 35-year-old, humeral shaft fracture, radial nerve palsy, intraoperative exploration demonstrating nerve entrapment in the fracture site. The question asks for optimal management of the nerve injury when the nerve is entrapped but not described as transected.\\n\\nBest interpretation: In fracture-associated radial nerve palsy where the nerve is found contused/entrapped in callus or fracture fragments but in continuity, standard management is surgical neurolysis (freeing the nerve) combined with fracture fixation, then observation for recovery. This aligns directly with option B.\\n\\nOption appraisal:\\n- A (Immediate nerve grafting): Indicated for segmental loss or transection, not mere entrapment in continuity.\\n- B (Neurolysis and fracture fixation): Correct; standard of care when nerve is intact but entrapped.\\n- C (Nerve transfer from triceps branch): Reserved for irreparable/high radial nerve lesions or failed recovery, not first-line here.\\n- D (Tendon transfer for wrist extension): Salvage for chronic, irrecoverable palsy after 12–18 months.\\n- E (Observation with serial EMG): Appropriate only if no indication for exploration; here entrapment has been identified.\\n\\nMain medical/logical issues: None significant.\\nMinimal fix: Explicitly state the nerve is in continuity/contused but not transected to remove any ambiguity favoring grafting.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 35-year-old, humeral shaft fracture, radial nerve palsy, intraoperative exploration demonstrating nerve entrapment in the fracture site. The question asks for optimal management of the nerve injury when the nerve is entrapped but not described as transected.\n\nBest interpretation: In fracture-associated radial nerve palsy where the nerve is found contused/entrapped in callus or fracture fragments but in continuity, standard management is surgical neurolysis (freeing the nerve) combined with fracture fixation, then observation for recovery. This aligns directly with option B.\n\nOption appraisal:\n- A (Immediate nerve grafting): Indicated for segmental loss or transection, not mere entrapment in continuity.\n- B (Neurolysis and fracture fixation): Correct; standard of care when nerve is intact but entrapped.\n- C (Nerve transfer from triceps branch): Reserved for irreparable/high radial nerve lesions or failed recovery, not first-line here.\n- D (Tendon transfer for wrist extension): Salvage for chronic, irrecoverable palsy after 12–18 months.\n- E (Observation with serial EMG): Appropriate only if no indication for exploration; here entrapment has been identified.\n\nMain medical/logical issues: None significant.\nMinimal fix: Explicitly state the nerve is in continuity/contused but not transected to remove any ambiguity favoring grafting.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-017", "question": "A 65-year-old man with Parkinson's disease develops impulse control disorder on pramipexole. He also has motor fluctuations. What is the most appropriate medication adjustment?", "options": ["Switch to rotigotine patch", "Add entacapone", "Initiate deep brain stimulation evaluation", "Start apomorphine subcutaneous", "Convert to levodopa-benserazide"], "answer": "D", "answer_index": 3, "explanation": "Apomorphine provides rapid relief for fluctuations and may reduce dopamine agonist dose, mitigating ICD. Rotigotine similar risk, entacapone extends levodopa, DBS for advanced, levodopa increases dyskinesia risk.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K\\nVerdict on keyed answer: Miskeyed — better alternative exists\\nKey stem clues: 65-year-old man with Parkinson’s disease, currently on pramipexole, has developed an impulse control disorder (ICD) and has motor fluctuations. Question asks for the most appropriate medication adjustment.\\nICD is strongly associated with dopamine agonists such as pramipexole. Standard management is reduction or discontinuation of the dopamine agonist and conversion to levodopa-based therapy, which has a much lower ICD risk. Option E (convert to levodopa-benserazide) directly addresses the etiologic agent (pramipexole) and is guideline-consistent. Apomorphine (D) is a potent dopaminergic rescue therapy and itself a dopamine agonist; using it to manage chronic motor fluctuations while maintaining pramipexole does not reliably reduce ICD risk and may worsen it. The provided rationale that apomorphine “may reduce dopamine agonist dose, mitigating ICD” is speculative and not standard of care.\\nThus, there is a unique best answer (E), but the key is incorrect.\\nMinimal fix: Change the keyed correct answer from D to E, and adjust the explanation to emphasize withdrawal of pramipexole and conversion to levodopa-benserazide as the appropriate response to ICD with motor fluctuations.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K\nVerdict on keyed answer: Miskeyed — better alternative exists\nKey stem clues: 65-year-old man with Parkinson’s disease, currently on pramipexole, has developed an impulse control disorder (ICD) and has motor fluctuations. Question asks for the most appropriate medication adjustment.\nICD is strongly associated with dopamine agonists such as pramipexole. Standard management is reduction or discontinuation of the dopamine agonist and conversion to levodopa-based therapy, which has a much lower ICD risk. Option E (convert to levodopa-benserazide) directly addresses the etiologic agent (pramipexole) and is guideline-consistent. Apomorphine (D) is a potent dopaminergic rescue therapy and itself a dopamine agonist; using it to manage chronic motor fluctuations while maintaining pramipexole does not reliably reduce ICD risk and may worsen it. The provided rationale that apomorphine “may reduce dopamine agonist dose, mitigating ICD” is speculative and not standard of care.\nThus, there is a unique best answer (E), but the key is incorrect.\nMinimal fix: Change the keyed correct answer from D to E, and adjust the explanation to emphasize withdrawal of pramipexole and conversion to levodopa-benserazide as the appropriate response to ICD with motor fluctuations.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-018", "question": "A 50-year-old woman with migraine presents with hemiplegic episodes and family history of similar symptoms. Genetic testing reveals CACNA1A mutation. What is the most effective prophylactic treatment?", "options": ["Verapamil extended-release", "Topiramate", "Propranolol", "Amitriptyline", "Valproate"], "answer": "A", "answer_index": 0, "explanation": "Verapamil is preferred for familial hemiplegic migraine due to calcium channel involvement. Topiramate and valproate for common migraine, propranolol beta-blockade, amitriptyline for tension overlap.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: middle‑aged woman with migraine; hemiplegic episodes; positive family history; confirmed CACNA1A mutation (P/Q–type voltage-gated calcium channel). The question asks for most effective prophylactic therapy specifically for familial hemiplegic migraine with a known calcium-channel mutation. Among standard preventives listed, verapamil (a calcium channel blocker) directly targets the implicated channel type and is commonly cited as a preferred/characteristic option for familial hemiplegic migraine in exam-style teaching. Other listed agents (topiramate, propranolol, amitriptyline, valproate) are conventional migraine preventives but not specifically favored for hemiplegic/familial forms, and some guidelines caution about typical vasoconstrictive migraine drugs but do not highlight these as uniquely best here. Thus A is uniquely best in this exam framing.\\nMain medical accuracy issues: None major; the teaching point (calcium-channel mutation → calcium-channel blocker prophylaxis) is consistent with board-level expectations, though real-world evidence is limited.\\nMinimal fix: Explicitly state “familial hemiplegic migraine” in the stem to fully align clinical label with the genetic finding and treatment rationale.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: middle‑aged woman with migraine; hemiplegic episodes; positive family history; confirmed CACNA1A mutation (P/Q–type voltage-gated calcium channel). The question asks for most effective prophylactic therapy specifically for familial hemiplegic migraine with a known calcium-channel mutation. Among standard preventives listed, verapamil (a calcium channel blocker) directly targets the implicated channel type and is commonly cited as a preferred/characteristic option for familial hemiplegic migraine in exam-style teaching. Other listed agents (topiramate, propranolol, amitriptyline, valproate) are conventional migraine preventives but not specifically favored for hemiplegic/familial forms, and some guidelines caution about typical vasoconstrictive migraine drugs but do not highlight these as uniquely best here. Thus A is uniquely best in this exam framing.\nMain medical accuracy issues: None major; the teaching point (calcium-channel mutation → calcium-channel blocker prophylaxis) is consistent with board-level expectations, though real-world evidence is limited.\nMinimal fix: Explicitly state “familial hemiplegic migraine” in the stem to fully align clinical label with the genetic finding and treatment rationale.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-019", "question": "A 40-year-old man with HIV on antiretroviral therapy develops violaceous plaques on the legs. Biopsy shows spindle cells and HHV-8 positivity. What is the most appropriate systemic therapy?", "options": ["Liposomal doxorubicin", "Interferon-alpha", "Thalidomide", "Sirolimus", "Rituximab"], "answer": "D", "answer_index": 3, "explanation": "Sirolimus inhibits mTOR in AIDS-related Kaposi sarcoma, reducing progression in immunocompromised patients. Doxorubicin for advanced, interferon immunomodulation, thalidomide anti-angiogenic but toxic, rituximab for lymphoid.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K (likely also M). Verdict on keyed answer: Miskeyed. The vignette clearly describes AIDS-related Kaposi sarcoma (HIV patient, violaceous plaques, spindle cells, HHV-8+). The question asks for the most appropriate systemic therapy. Standard, guideline-supported first-line systemic therapy for advanced/symptomatic Kaposi sarcoma in HIV patients is liposomal doxorubicin (or paclitaxel), not sirolimus, which is mainly used in transplant/iatrogenic KS due to its immunosuppressive/mTOR effects and not as established first-line in AIDS-KS. Thus option A is the best-supported answer; D is not. Key stem clues: HIV-positive, biopsy-proven Kaposi sarcoma, asking for systemic therapy. Main logical issue: there is a unique best answer (A) based on mainstream oncology and HIV guidelines, but the provided key points to D, creating a miskey. Additionally, some options (interferon-alpha, thalidomide) could be used in select settings, making D even less clearly best. Main medical accuracy issue: overstatement of sirolimus as preferred systemic therapy in AIDS-related KS. Minimal fix: Change the keyed correct answer from D to A, or rewrite stem to specify post–solid organ transplant KS on calcineurin inhibitors where sirolimus is preferred.\",\n  \"medical_accuracy_score\":  \t\"3\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (likely also M). Verdict on keyed answer: Miskeyed. The vignette clearly describes AIDS-related Kaposi sarcoma (HIV patient, violaceous plaques, spindle cells, HHV-8+). The question asks for the most appropriate systemic therapy. Standard, guideline-supported first-line systemic therapy for advanced/symptomatic Kaposi sarcoma in HIV patients is liposomal doxorubicin (or paclitaxel), not sirolimus, which is mainly used in transplant/iatrogenic KS due to its immunosuppressive/mTOR effects and not as established first-line in AIDS-KS. Thus option A is the best-supported answer; D is not. Key stem clues: HIV-positive, biopsy-proven Kaposi sarcoma, asking for systemic therapy. Main logical issue: there is a unique best answer (A) based on mainstream oncology and HIV guidelines, but the provided key points to D, creating a miskey. Additionally, some options (interferon-alpha, thalidomide) could be used in select settings, making D even less clearly best. Main medical accuracy issue: overstatement of sirolimus as preferred systemic therapy in AIDS-related KS. Minimal fix: Change the keyed correct answer from D to A, or rewrite stem to specify post–solid organ transplant KS on calcineurin inhibitors where sirolimus is preferred.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-020", "question": "A 60-year-old man with chronic kidney disease stage 4 presents with hematuria and flank pain. Imaging shows a Bosniak IV cyst with enhancing nodule. What is the most appropriate management?", "options": ["Partial nephrectomy", "Active surveillance", "Radiofrequency ablation", "Percutaneous biopsy", "Radical nephrectomy"], "answer": "A", "answer_index": 0, "explanation": "Partial nephrectomy preserves renal function in CKD while addressing malignant potential of Bosniak IV cyst. Surveillance for lower categories, ablation for small tumors, biopsy diagnostic not therapeutic, radical sacrifices nephrons.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 60-year-old man, stage 4 chronic kidney disease, hematuria and flank pain, imaging shows a Bosniak IV renal cyst with an enhancing nodule. Bosniak IV implies a very high likelihood of malignancy and generally warrants definitive treatment. Concurrent stage 4 CKD makes nephron-sparing particularly important to delay progression to end-stage kidney disease.\\n\\nManagement: For a clearly malignant-appearing lesion (Bosniak IV), surgical excision is standard. In a patient with significant CKD and a presumably localized, resectable lesion, partial nephrectomy is preferred over radical nephrectomy to preserve renal function while providing oncologic control. Active surveillance is inappropriate for Bosniak IV; radiofrequency ablation is reserved mainly for small solid renal masses, often in patients unfit for surgery, and is less standard for complex cystic masses. Percutaneous biopsy is diagnostic, not definitive treatment, and not typically needed for a Bosniak IV lesion given its high malignancy probability.\\n\\nMain medical accuracy issues: None substantive; the teaching point aligns with guideline‑level practice, though real-world decisions would consider lesion size/location and surgical risk.\\n\\nMinimal fix: Specify lesion size (e.g., “3-cm Bosniak IV cyst in an otherwise resectable location”) to reinforce suitability of partial nephrectomy over ablation or radical nephrectomy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 60-year-old man, stage 4 chronic kidney disease, hematuria and flank pain, imaging shows a Bosniak IV renal cyst with an enhancing nodule. Bosniak IV implies a very high likelihood of malignancy and generally warrants definitive treatment. Concurrent stage 4 CKD makes nephron-sparing particularly important to delay progression to end-stage kidney disease.\n\nManagement: For a clearly malignant-appearing lesion (Bosniak IV), surgical excision is standard. In a patient with significant CKD and a presumably localized, resectable lesion, partial nephrectomy is preferred over radical nephrectomy to preserve renal function while providing oncologic control. Active surveillance is inappropriate for Bosniak IV; radiofrequency ablation is reserved mainly for small solid renal masses, often in patients unfit for surgery, and is less standard for complex cystic masses. Percutaneous biopsy is diagnostic, not definitive treatment, and not typically needed for a Bosniak IV lesion given its high malignancy probability.\n\nMain medical accuracy issues: None substantive; the teaching point aligns with guideline‑level practice, though real-world decisions would consider lesion size/location and surgical risk.\n\nMinimal fix: Specify lesion size (e.g., “3-cm Bosniak IV cyst in an otherwise resectable location”) to reinforce suitability of partial nephrectomy over ablation or radical nephrectomy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]